Akin to left heart failure, it has been postulated that RVD is characterized by abnormal energy metabolism. 8, 9 Studies in animal models have demonstrated that RVD exhibits an increased expression of glycolysis-related genes 10 and increased enzymatic glycolysis rate. 11 However, it is largely unknown to what extent this switch in cardiac bioenergetics (also known as metabolic remodeling) 12 involves changes in fatty acid oxidation (FAO), whether metabolic remodeling is an adaptive response to chronic pressure overload, or to what extent mitochondrial structure and function are also compromised in RVD. Thus, we sought to do the following: (1) characterize the metabolic gene expression profile associated with RVD; (2) determine whether pressure-overload is sufficient to explain metabolic gene remodeling; and (3) assess the structure and function of mitochondria in the dysfunctional right ventricle.
Here, we report that RVD, as assessed in rat and human RV tissue samples, is characterized by a downregulation of PGC-1α expression and decreased expression of several PGC-1α target genes encoding key enzymes that regulate FAO, as well as other genes involved in mitochondrial biogenesis. In addition, we present evidence for impaired mitochondrial structure and function (respiration). Some of these findings have been reported previously in abstract form. 13, 14 Methods Animal Models
SU5416/Hypoxia Model (SuHx)
An animal model of severe angioproliferative PAH and RVD was generated in male Sprague-Dawley rats (body weight, 200 g; age, 6 weeks) with a 20-mg/kg, 1-time subcutaneous injection of a vascular endothelial growth receptor blocker (SU5416), followed by 4 weeks of 10% hypoxia, as described previously 15, 16 and in the online-only Data Supplement. On return to normoxia, RV function was evaluated by transthoracic echocardiogram. The tricuspid annular plane systolic excursion was the reference parameter for RV function. For hemodynamic measurements, median sternotomy was performed, and RV systolic pressure was measured with a 4.5-mm Millar conductance catheter inserted at the RV outflow tract. As described previously, the RV in the SuHx rat model responds to pulmonary hypertension with a robust degree of hypertrophy, followed by dysfunction and failure. 17 The RV in this rat model is characterized by fibrosis, capillary rarefaction, and cardiomyocyte apoptosis, 15 which are associated with decreased cardiac output, markedly dilated RV, and decreased exercise capacity. 18 As described previously, the SuHx RVD model reproduces some features of human RVD, such as paradoxical septal movement and RV dilatation (online-only Data Supplement Movie I).
Pulmonary Artery Banding
Surgical ligation of the pulmonary artery was achieved through a left thoracotomy in male Sprague-Dawley rats weighing 180 to 200 g, with a silk suture tied around an 18-gauge needle alongside the pulmonary artery, as described previously 15 (also in online-only Data Supplement). The pulmonary artery banding (PAB) rats were killed to collect organs 6 weeks after the surgery to allow for significant hypertrophy, as reported by Bogaard et al. 15, 19 As a model of strictly mechanical RV pressure overload, the PAB rat model demonstrates preserved RV function despite generating significantly high RV afterload and hypertrophy 15, 19 (Figure S1F through S1H, available in the online-only Data Supplement). Thus, the PAB model was used as a model of nondysfunctional RV hypertrophy and was studied as above. The Table presents the echocardiographic and hemodynamic data illustrating the degree of pulmonary hypertension and RV function in all of the conditions studied.
Human samples were obtained from patients diagnosed with PAH who underwent cardiac transplantation. Oxygen consumption by intact mitochondria was measured with Clark-type oxygen electrodes. Immunohistochemistry and gene and protein expression studies were performed with standard procedures, as outlined in the online-only Data Supplement Methods section.
Statistical Analysis
Differences between groups were assessed with 1-way or 2-way ANOVA or Kruskal-Wallis tests. Bonferroni and Dunn post hoc tests were used to assess significant differences between groups. A P value <0.05 was accepted as significant. Correlation analysis was done with a Spearman test. Results are reported as mean±SEM or fold-change mean±SEM unless specified otherwise. Four to 6 rats were used per group, unless otherwise specified. Statistical analysis was done with PASW V.18 (IBM, Armonk, NY) and GraphPad Prism (La Jolla, CA). For detailed information regarding echocardiography, hemodynamic measurements, gene expression, protein expression, human samples, mitochondrial isolation, measurement of mitochondrial respiration, chromatography electrospray ionization tandem mass spectrometry and immunohistochemistry, see the online-only Data Supplement.
Results

RVD Is Characterized by a Load-Independent Downregulation of PGC-1α, PPAR-α, and ERR-α
We have reported previously that dysfunctional RVs from SuHx-rats differentially express multiple gene signaling pathways when compared with nondysfunctional hypertrophied RVs. 20 Importantly, we reported that RVD is associated with gene expression changes that suggest an abnormal metabolism, with a particularly strong signal relating to the PPAR signaling pathways. Therefore, as a first step, we measured the expression of PGC-1α, a direct coactivator and master regulator of the PPAR family of transcription factors. PGC-1α regulates oxidative metabolism and many aspects of mitochondrial biology. 21 Western blots of protein samples obtained from SuHx RV tissues showed a significantly decreased amount of PGC-1α protein ( Figure 1A ). Quantitative polymerase chain reaction analysis revealed a significant downregulation of PGC-1α mRNA levels ( Figure 1B) , indicating that the change in PGC-1α expression also occurred on the transcription level. Decreased PGC-1α gene expression was accompanied by a decreased expression of the ERR-α and PPAR-α genes ( Figure  1B ). To evaluate whether pure mechanical RV pressure-overload was sufficient to downregulate PGC-1α expression, we measured PGC-1α transcript levels in PAB-RV tissues and found that the expression of PGC-1α, ERR-α, and PPAR-α was not significantly decreased in the nonfailing hypertrophied RVs of PAB rats, despite the high RV pressure and RV hypertrophy ( Figure 1B) . Figures 1C and Figure S2A and S2B (available in the online-only Data Supplement) illustrate that PGC-1α (R 2 =0.72; p=0.001), PPAR-α (R 2 =0.72, P=0.001), and ERR-α (R 2 =0.76; P=0.002) transcript levels strongly correlated with the tricuspid annular plane systolic excursion, a heart rate-independent variable of RV function.
We have described previously that SU5416 treatment alone does not induce RVD and has a limited impact on gene expression. 20 However, because decreased expression of PGC-1α could be a direct effect of the combination of SU5416 and hypoxia rather than a consequence of RVD, we measured the expression of PGC-1α 1 week after the SuHx protocol had been initiated. At 1 week no RVD is present and, indeed, as shown in Figure 1D , PGC-1α expression is not decreased in the right ventricle or in the left ventricle. In addition, we measured the expression of PGC-1α in rat lung tissues after 4 weeks of SuHx, a time point where plexiform-like lesions have already formed, and we found a significant increase in PGC-1α expression ( Figure 1E ). To further evaluate a potential toxic effect of SU5416 in the setting of RV pressure overload, we examined the RV gene expression of PAB animals exposed to SU5416 and found no change in the PGC-1α, ERR-α, or PPAR-α mRNA transcript levels ( Figure S2C ). Next, we measured the expression of PGC-1α in LV tissue obtained from animals killed 4 weeks after initiation of the SuHx protocol. Although somewhat decreased, the SuHx-LV tissue did not show a significant change in PGC-1α expression ( Figure S2D ). In the aggregate, the data indicate that the decreased expression of PGC-1α is unlikely attributed to a toxic effect of SU5416.
Because nuclear receptors other than PGC-1α have been implicated in phenotypic metabolic changes that occur during normal cardiac development, we decided to evaluate the expression of the ERR-γ and of the transcription factors COUP-TF1 and SP1. 22, 23 Quantitative polymerase chain reaction analysis showed that the expression of these transcription factors was not affected in dysfunctional RV tissues ( Figure S2E ). Lastly, to examine whether the changed expression of the metabolic gene pattern was also observed in human myocardium, we examined the gene expression of PGC-1α, PPAR-α, and ERR-α in RV tissue samples from patients with PAH. Indeed, we found a comparable expression pattern in the human RV tissue as we had observed in the SuHx RV rat tissue ( Figure 1F ). In accordance with our previous reports, 20 dysfunctional RV hypertrophy in the SuHx rats was characterized by increased expression of GLUT1 and hexokinase 1; these 2 genes play an important role in glycolysis ( Figure 2D ). In contrast, we found a downregulation of genes that encode enzymes involved in aerobic glucose catabolism, such as the genes encoding the Krebs cycle enzymes citrate synthase and isocitrate dehydrogenase. Furthermore, the β subunit of pyruvate dehydrogenase, an important link between glycolysis and glucose oxidation, showed a 50% decreased mRNA expression, whereas the gene expression of pyruvate dehydrogenase kinase, an enzyme controlling pyruvate dehydrogenase activity, was upregulated. Conversely, nonfailing hypertrophied PAB RVs exhibited a normal expression of glycolysis-related genes, a significantly lower expression of pyruvate dehydrogenase kinase, and normal expression of isocitrate dehydrogenase and citrate synthase ( Figure 2D ).
Dysfunctional RV Hypertrophy Is Characterized by Decreased Expression of Genes Involved in Fatty Acid and Glucose Oxidation
RVD Is Characterized by Abnormal Mitochondrial Ultrastructure, Impaired Mitochondrial Respiration, and Abnormal Mitochondrial Biogenesis
PGC-1α regulates mitochondrial biogenesis along with oxidative metabolism. 21 Therefore, we sought to explore abnormalities in mitochondrial biology. PGC-1α exerts pleiotropic effects by direct coactivation of an array of nuclear and nonnuclear receptors used in the control of cellular metabolism. 21 Among them, transcription factor A, mitochondrial (TFAM), Figure 2 . A, mRNA levels of genes encoding key rate-limiting enzymes involved in fatty acid transport into the cell (CD36) and transport into the mitochondria (ACSL1, CPT1α, CPT1β, and CPT2) were decreased. B, Genes encoding a family of acyl-coenzyme A (CoA) dehydrogenases specific for fatty acid β-oxidation (ACADS, ACADM, and ACADVL) also were downregulated in dysfunctional SU5416/hypoxia (SuHx) right ventricles but significantly increased in pulmonary artery banding (PAB) right ventricular (RV) tissue. C, Western blotting on cytosolic protein extracts obtained from RV tissue lysate shows decreased protein expression of ACADM and ACADVL in SuHx-RV tissue. D, Genes encoding key rate-limiting enzymes for aerobic glucose oxidation (Kreb cycle) were downregulated, whereas genes encoding enzymes necessary for glycolysis were upregulated. Data are shown in fold changes±SEM over controls; *P<0.01; #P<0.0001.
regulates mitochondrial DNA replication and maintenance and is required for cellular and mitochondrial viability. 24, 25 Associated with the decreased expression of PGC-1α, SuHx-RVD tissue had a decreased expression of TFAM ( Figure 3A ). Because reduced TFAM mRNA levels are associated with alterations in mitochondrial biogenesis, we measured the expression of Top1mt, POGL2, and POLRMT, a set of genes that encode enzymes required for the replication of mtDNA and mitochondrial biogenesis. 4, 25 All 3 of the genes were downregulated in dysfunctional (SuHx) RV hypertrophy but not in PAB-induced RV hypertrophy, as illustrated in Figure  3A . To test for decreased mtDNA transcription, we measured the expression of 2 mtDNA-encoded proteins, NADH-ubiquinone oxidoreductase subunit 4L and cytochrome B. These 2 proteins are subunits of the mitochondrial electron-transport chain complexes I and III, respectively. As illustrated in Figure 3B , the relative protein expression of NADH-ubiquinone oxidoreductase subunit 4L and cytochrome B was significantly decreased in SuHx-RVs.
High-power magnification electron microscopy demonstrated that the mitochondrial ultrastructure in RVD tissue was highly abnormal. In comparison to controls ( Figure  3C ), mitochondria in SuHx RVs were consistently abnormal in shape and size and clumped together in clusters ( Figure  3D ). Although clustering of mitochondria was also present in the PAB RVs ( Figure 3E, arrow) , the overall distribution of mitochondria was similar to that of control RVs. On isolation, RVD tissues exhibited a significantly decreased amount of mitochondria, as evidenced by mitochondrial yield and by citrate synthase activity ( Figure 4A and 4B) . Isolated mitochondria were studied by respirometry to evaluate the efficiency of oxidative phosphorylation. RVF mitochondria demonstrated a significantly decreased ADP-stimulated (state 3) respiration rate when using glutamate ( Figure 4C ) but not when using succinate as electron donors to complexes I and II, respectively (Table S2 ). The complete respirometry results are depicted in Table S2 .
Because mitochondrial dysfunction could contribute to the generation of reactive oxygen species (ROS), we measured the levels of 8-isoprostane (8-isoProstaglandin F 2α ) in RVD tissues. 8-Isoprostane has been proposed as a marker of antioxidant deficiency and enhanced oxidative stress. 26 Analysis from liquid chromatography-tandem mass spectrometry of SuHx RV tissue demonstrated no change in the amount of 8-isoprostane in comparison with controls ( Figure S3A ) but increased levels in the lungs ( Figure S3B ). However, although the amount of ROS generated might have not been sufficient to cause significant lipid peroxidation in whole RV tissues, ROS could still induce damage. mtDNA is particularly susceptible to ROS-induced damage, 27 and a common marker of mtDNA damage is the formation of 7,8-dihydro-8-oxoguanine, a mutagenic base byproduct that results from direct exposure of DNA to ROS. 28 Figure 5 shows 8-oxo-G-positive staining in dysfunctional RV tissues, particularly in the endomyocardial area.
Discussion
RV failure is a common consequence of severe chronic pulmonary hypertension and the most frequent cause of death in patients with PAH. 1 Although RVD plays an important prognostic role in patients with PAH, 29, 30 there are relatively few experimental data shedding light on the mechanisms of chronic RVD and failure. 31, 32 Although it has been proposed that RVD is associated with metabolic gene remodeling, 8 a comprehensive metabolic gene profile of the failing right ventricle is still lacking.
Here we demonstrate that dysfunctional RV hypertrophy, in rats and patients with PAH, exhibits a significant reduction in the expression of PGC-1α and its corresponding nuclear receptors (PPAR-α and ERR-α). Interestingly, the change in PGC-1α expression seems to be largely independent of the RV pressure-overload and hypertrophy. Moreover, multiple PGC-1α target genes encoding proteins required for fatty acid metabolism were significantly decreased in expression in RVD tissues. Particularly, the expression of genes encoding the acyl-CoA dehydrogenases, which are specific for fatty acid β-oxidation, was significantly decreased in dysfunctional SuHx-RV hypertrophy but not in adaptive PAB-RV hypertrophy. Conversely, functional PAB-RV hypertrophy was associated with a high expression of ACADS and ACADVL, the latter being the most important heart acyl-CoA dehydrogenase for FAO. Altogether, the gene and protein expression data suggest that, in RVD, FAO is impaired on multiple levels. Along with the metabolic gene remodeling, we show evidence for an abnormal mitochondrial ultrastructure and decreased mitochondrial respiration at the level of complex I of the electron transport chain. Moreover, RVD is characterized by decreased expression of genes encoding proteins required for mitochondrial biogenesis, such as TFAM, Top1mt, POGL2, and POLRMT. RVD also demonstrated a significantly low mitochondrial yield in comparison with control RVs. Finally We decided to focus on central transcriptional regulators, such as PGC-1α and its corresponding nuclear receptors ERRα and PPAR-α, because multiple gene knockout studies have illustrated that these proteins play an important role during the functional bioenergetic adaptation of the heart-to-pressure overload. 21, 29, 30 PGC-1α is preferentially expressed in tissues with high oxidative capacity and coordinates several biological processes of mammalian energy metabolism by activating genes involved in cellular uptake and mitochondrial oxidation of fatty acids. 33 Heart tissue obtained from PGC-1α knockout mice displays a reduced palmitoyl-L-carnitine state 3 respiration, suggesting reduced FAO, and a reduction in the amount of ATP generated per oxygen consumed. 34 Of equal importance, in the absence of PGC-1α, the expression of mitochondrial genes in the heart is suppressed, the activities of mitochondrial enzymes are altered, and ATP production is reduced. 35 As has been shown in models of left heart failure, 7, 35, 36 the SuHx model of severe PAH and RVD is characterized by reduced PGC-1α expression ( Figure 1A-B ). We consider this reduced expression as a central component of RV metabolic remodeling. Although downregulation of PGC-1α is a feature of dysfunctional hypertrophy, it remains unclear what drives the downregulation of PGC-1α expression during RVD. Because the SuHx model is characterized by capillary rarefaction, 15 ischemia and hypoxia could potentially drive the metabolic remodeling. However, PGC-1α expression is not decreased until RVD occurs. Because PGC-1α expression is a hypoxiainducible factor-independent hypoxia-inducible gene, 37 it is unlikely that the downregulated expression of PGC-1α and the associated metabolic remodeling profile would be entirely explained by hypoxia or by hypoxia-inducible factor activation. Although decreased PGC-1α mRNA expression has been reported in human left heart failure, 38 recent studies using samples of left ventricles obtained from patients with heart failure have demonstrated a relatively normal expression of PGC-1α. 4 Perhaps these discrepant results may be explained by different drug treatments of the patients with LV failure.
Although impaired glucose oxidation has been well characterized in the monocrotaline-injury model of RVD, changes in fatty acid metabolism are less clear. 39 In our study, the downregulation of PGC-1α, ERR-α, and PPAR-α expression was coupled to a decreased expression of genes encoding fatty acid transport proteins and FAO, which suggests to us that fatty acid catabolism in the failing RVs is likely compromised on the levels of regulation, transport, and catabolism. Others have reported that changes in FAO occur in the monocrotaline-injury model of PH, mainly in carnitine palmitoyltransferase-1β expression, 40 and few case reports have shown reduced uptake of radiolabeled fatty acid analogues in the RV of patients with PAH. 41 However, it remains unclear whether the changes in fatty acid metabolism are beneficial or detrimental in the overall function of the right ventricle. In the left ventricle, multiple studies have shown that the rate FAO is preserved or increased in physiological/adaptive hypertrophy and that FAO decreases during the progression of heart failure. 42 Similarly, we demonstrate a normal/increased expression of ACADM, ACADS, and ACADVL in adaptive PAB-RV hypertrophy. These results are supported by the data of Fang et al, 43 who demonstrated that rats with PAB-RV hypertrophy exhibit higher rates of FAO. We postulate that, along with capillary rarefaction, fibrosis, and ROS-induced damage, mitochondrial metabolic remodeling in RVD is pathological. It has been reported that FAO inhibition may have a therapeutic potential 43 ; however, it will remain to be tested whether further inhibition of FAO is beneficial in the model of SuHx RVD.
Although it has been reported that RVD is associated with mitochondrial hyperpolarization, 44 a comprehensive analysis of mitochondrial respiration in RVD is still lacking. Here we demonstrate that RVD is associated with significant mitochondrial dysfunction, reduced mitochondrial yield, and reduced overall oxidative capacity. Surprisingly, although the expression of PGC-1α and TFAM was unchanged in PAB-RV hypertrophy, mitochondrial yield and citrate synthase activity were similarly decreased in both SuHx-RVD and PAB-RV hypertrophy. Because PGC-1α regulates mitochondrial biogenesis, our results would suggest an uncoupling between PGC-1α expression and mitochondrial biogenesis in adaptive PAB-RV hypertrophy. Yet, abnormal mitochondrial biogenesis can occur in the presence of normal PGC-1 levels. 4 We speculate that preserved PGC-1α and TFAM expression could explain the better preserved mitochondrial respiration in PAB-RV hypertrophy when compared with SuHx-RVD, because both proteins play a critical role in mitochondrial function. 21, 25 
Study Limitations and Future Directions
We do not know whether a decrease of PGC-1α expression is a consequence or a cause of RVF. Nonetheless, our results show that decreased PGC-1α gene expression is not explained by a toxic effect of SU5416, hypoxia, or RV pressure overload. Several mechanisms may participate in the downregulation of PGC-1α expression in RVD and the associated gene metabolic remodeling. We did not explore whether the metabolic remodeling-dependent gene and protein expression profile affects enzymatic activity.
Conclusions
Our data illustrate that RVD is associated with a complex multilevel disturbance of FAO and mitochondrial respiration that is not entirely explained by pressure-overload or hypertrophy. We propose that RV metabolic remodeling is a consequence of decreased PGC-1α expression. To what extent metabolic remodeling or mitochondrial dysfunction is of functional importance for the development of RVD remains to be investigated.
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